Effect of Vortioxetine treatment on gene expression of LN-229 glioblastoma cells over time

The atypical antidepressant Vortioxetine represents the most effective neuroactive drug with anti-glioblastoma efficacy across glioblastoma patient samples and model systems. To closer examine the temporal dynamics of Vortioxetine, we performed in-depth transcriptomic profiling of LN-229 cells following Vortioxetine treatment. We performed gene expression profiling analysis using data obtained from RNA-seq across 6 different time points during the 24 hours following Vortioxetine treatment. Overall design: Comparative gene expression profiling analysis of RNA-seq data for LN-229 glioblastoma cells at baseline then at each respective time point after Vortioxetine treatment